US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Inc (CRVS) ニュース

CRVS

Corvus Pharmaceuticals (CRVS)

Corvus Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CRVS

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	06 : 19	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/08	06 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/08	06 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/07	05 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/07	05 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/07	05 : 01	GlobeNewswire Inc.	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/03	05 : 02	GlobeNewswire Inc.	Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/05/02	21 : 30	GlobeNewswire Inc.	Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/04/10	05 : 01	GlobeNewswire Inc.	Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/03/20	05 : 02	GlobeNewswire Inc.	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/03/19	20 : 27	IH Market News	US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/03/14	05 : 02	GlobeNewswire Inc.	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/03/02	07 : 57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/02/12	22 : 30	GlobeNewswire Inc.	Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/02/09	06 : 27	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/02/09	06 : 05	GlobeNewswire Inc.	Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/02/07	06 : 05	GlobeNewswire Inc.	Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/01/24	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2024/01/24	07 : 00	GlobeNewswire Inc.	Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/12/10	02 : 00	GlobeNewswire Inc.	Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/12/09	06 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/12/09	06 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/08	06 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/08	06 : 02	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/08	06 : 01	GlobeNewswire Inc.	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/02	22 : 15	GlobeNewswire Inc.	Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/02	08 : 31	GlobeNewswire Inc.	Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/11/01	05 : 02	GlobeNewswire Inc.	Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/09/07	05 : 05	GlobeNewswire Inc.	Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA	NASDAQ:CRVS	Corvus Pharmaceuticals Inc
2023/08/09	05 : 02	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CRVS	Corvus Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:CRVS

1 2 3 4 5 6 7 8 9 10 次へ >>

Gold vs US Dollar

Health Care Select Sector

Energy Select Sector SPDR

Financial Select Sector

US Dollar vs Euro

Deutsche Telekom (QX)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約